Table 3.
Incidence rates of the qualitative parameters
| Month | IAI (n=29) | IVR (n=74) | P-value | ||
|---|---|---|---|---|---|
| ELM disruption | |||||
| 1 | 3 | 10.3% | 4 | 5.4% | 0.079 |
| 2 | 1 | 3.4% | 8 | 10.8% | 0.099 |
| 3 | 2 | 6.9% | 9 | 12.2% | 0.036 |
| Disruption of ellipsoid line | |||||
| 1 | 12 | 72.4% | 21 | 28.4% | 0.243 |
| 2 | 14 | 58.6% | 28 | 37.8% | 0.377 |
| 3 | 9 | 55.2% | 20 | 27.0% | 0.808 |
| SRD | |||||
| 1 | 10 | 34.5% | 41 | 55.4% | 0.079 |
| 2 | 6 | 20.7% | 26 | 35.1% | 0.099 |
| 3 | 5 | 17.2% | 31 | 41.9% | 0.036 |
| PEE | |||||
| 1 | 21 | 72.4% | 63 | 85.1% | 0.161 |
| 2 | 17 | 58.6% | 62 | 83.8% | 0.008 |
| 3 | 16 | 55.2% | 58 | 78.4% | 0.030 |
| IRF | |||||
| 1 | 4 | 13.8% | 13 | 17.6% | 0.773 |
| 2 | 2 | 6.9% | 11 | 14.9% | 0.342 |
| 3 | 4 | 13.8% | 10 | 13.5% | 1.000 |
Abbreviations: ELM, external limiting membrane; IAI, intravitreal aflibercept injection; IVR, intravitreal ranibizumab injection; SRD, serous retinal detachment; PEE, pigment epithelial elevation; IRF, intra retinal fluid.